28127757|t|Donor bone marrow cells are essential for iNKT cell -mediated Foxp3 + Treg cell expansion in a murine model of transplantation tolerance
28127757|a|Mixed chimerism induction is the most reliable method for establishing transplantation tolerance. We previously described a novel treatment using a suboptimal dose of anti-CD40 ligand (anti-CD40L) and liposomal formulation of a ligand for invariant natural killer T cells administered to sub-lethally irradiated recipient mice after donor bone marrow cell (BMC) transfer. Recipient mice treated with this regimen showed expansion of a Foxp3 -positive regulatory T(Treg) cell phenotype, and formation of mixed chimera. However, the mechanism of expansion and bioactivity of Treg cells remains unclear. Here, we examine the role of donor BMCs in the expansion of bioactive Treg cells. The mouse model was transplanted with a heart allograft the day after treatment. The results showed that transfer of spleen cells in place of BMCs failed to deplete host interferon (IFN)-γ -producing CD8(+) T cells, expand host Ki67(+) CD4(+) CD25(+) Foxp3(+) Treg cells, and prolong graft survival. Severe combined immunodeficiency mice who received Treg cells obtained from BMC-recipients accepted skin grafts in an allo-specific manner. Myeloid-derived suppressor cells, which were a copious cell subset in BMCs, enhanced the Ki67 expression of Treg cells. This suggests that donor BMCs are indispensable for the expansion of host bioactive Treg cells in our novel treatment for transplant tolerance induction.
28127757	0	5	Donor	T098	C0013018
28127757	6	23	bone marrow cells	T025	C0005955
28127757	42	51	iNKT cell	T025	C2350467
28127757	62	67	Foxp3	T116,T123	C1505260
28127757	70	79	Treg cell	T025	C0039198
28127757	80	89	expansion	T043	C0007595
28127757	95	101	murine	T015	C0026809
28127757	102	107	model	T008	C0599779
28127757	111	136	transplantation tolerance	T040	C0887936
28127757	137	152	Mixed chimerism	T032	C0333678
28127757	153	162	induction	T045	C0017391
28127757	184	190	method	T170	C0025663
28127757	208	233	transplantation tolerance	T040	C0887936
28127757	267	276	treatment	T061	C0087111
28127757	285	300	suboptimal dose	T081	C0178602
28127757	304	320	anti-CD40 ligand	T121	C1254351
28127757	322	332	anti-CD40L	T121	C1254351
28127757	338	347	liposomal	T109	C0023828
28127757	348	359	formulation	T122	C0013058
28127757	376	408	invariant natural killer T cells	T025	C2350467
28127757	409	421	administered	T169	C1521801
28127757	425	437	sub-lethally	T033	C0243095
28127757	449	463	recipient mice	T015	C0025929
28127757	470	475	donor	T098	C0013018
28127757	476	492	bone marrow cell	T025	C0005955
28127757	494	497	BMC	T025	C0005955
28127757	499	507	transfer	T061	C0040732
28127757	509	523	Recipient mice	T015	C0025929
28127757	524	536	treated with	T061	C0332293
28127757	542	549	regimen	T061	C0040808
28127757	557	566	expansion	T043	C0007595
28127757	572	577	Foxp3	T116,T123	C1505260
28127757	588	611	regulatory T(Treg) cell	T025	C0039198
28127757	612	621	phenotype	T032	C0031437
28127757	640	653	mixed chimera	T001	C0206612
28127757	668	677	mechanism	T043	C0007613
28127757	681	690	expansion	T043	C0007595
28127757	695	706	bioactivity	T052	C0441655
28127757	710	720	Treg cells	T025	C0039198
28127757	747	754	examine	T033	C0332128
28127757	767	772	donor	T098	C0013018
28127757	773	777	BMCs	T025	C0005955
28127757	785	794	expansion	T043	C0007595
28127757	808	818	Treg cells	T025	C0039198
28127757	824	835	mouse model	T050	C2986594
28127757	840	852	transplanted	T061	C0040732
28127757	860	875	heart allograft	T023	C0564471
28127757	880	883	day	T079	C0439228
28127757	890	899	treatment	T061	C0087111
28127757	925	933	transfer	T061	C0040732
28127757	937	943	spleen	T023	C0037993
28127757	944	949	cells	T025	C0007634
28127757	962	966	BMCs	T025	C0005955
28127757	985	989	host	T026	C1819995
28127757	990	1008	interferon (IFN)-γ	T116,T121,T129	C3539881
28127757	1020	1034	CD8(+) T cells	T025	C0242629
28127757	1043	1047	host	T026	C1819995
28127757	1048	1090	Ki67(+) CD4(+) CD25(+) Foxp3(+) Treg cells	T025	C0039198
28127757	1104	1118	graft survival	T042	C0018131
28127757	1136	1152	immunodeficiency	T047	C0021051
28127757	1153	1157	mice	T015	C0025929
28127757	1171	1181	Treg cells	T025	C0039198
28127757	1196	1210	BMC-recipients	T101	C0376387
28127757	1220	1231	skin grafts	T122	C0181078
28127757	1260	1292	Myeloid-derived suppressor cells	T025	C4277543
28127757	1307	1326	copious cell subset	T025	C0007634
28127757	1330	1334	BMCs	T025	C0005955
28127757	1349	1353	Ki67	T116,T129,T130	C0208804
28127757	1354	1364	expression	T045	C1171362
28127757	1368	1378	Treg cells	T025	C0039198
28127757	1399	1404	donor	T098	C0013018
28127757	1405	1409	BMCs	T025	C0005955
28127757	1436	1445	expansion	T043	C0007595
28127757	1449	1453	host	T026	C1819995
28127757	1464	1474	Treg cells	T025	C0039198
28127757	1488	1497	treatment	T061	C0087111
28127757	1502	1532	transplant tolerance induction	T038	C1817969